Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in ...

Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

Eli Lilly’s Alzheimer’s drug, Kisunla, has received approval from the Japanese Ministry of Health, Labour and Welfare. This ...

Researchers are finding new ways to help people to detect Alzheimer’s in the early stages that makes life with the disease more livable.

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines – and a lot of older ...

In U.N. Speech, Biden Says World Faces an ‘Inflection Point’ Amid Turmoil The U.N. General Assembly has begun in New York City as conflicts rage across the world. In his final U.N. speech ...